BETHESDA, MARYLAND--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) reported today that the first patent related to Thymosin beta 4 (Tß4) for the treatment of Epidermolysis Bullosa (EB) has been issued in Australia. The patent, which expires in 2022, claims numerous compositions, uses and processes related to the Company’s intellectual property. Similar patent applications have been submitted throughout the world for EB, as have applications regarding diverse properties, uses and compositions related to RegeneRx’s technology platform beyond the wound healing field.
